Tag: coronavirus
The Role of Antiviral Treatment in the COVID-19 Pandemic
US Food and Drug Administration (FDA) issued an emergency use authorisation for Pfizer's COVID-19 antiviral, Paxlovid few weeks ago. Trial results released by the manufacturer indicate that the drug cuts the risk of hospitalisation... read more
Noninvasive Respiratory Support for COVID-19 Patients: When, for Whom, and How?
The significant mortality rate and prolonged ventilator days associated with invasive mechanical ventilation (IMV) in patients with severe COVID-19 have incited a debate surrounding the use of noninvasive respiratory support... read more
WHO Recommends Two New Drugs for COVID-19 Treatment
WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be. The... read more
Remdesivir Treatment for Hospitalized COVID-19 Patients in Canada
Remdesivir, when compared with standard of care, has a modest but significant effect on outcomes important to patients and health systems, such as the need for mechanical ventilation. Across 52 Canadian hospitals, we randomized... read more
Study Supports Remdesivir Treatment for COVID-19 Patients on Low-Flow Oxygen or No Oxygen
Remdesivir treatment increased the likelihood of clinical improvement in COVID-19 patients on low-flow oxygen or no oxygen, according to a new study by the Johns Hopkins University School of Medicine, the Johns Hopkins Bloomberg... read more
Efficacy of Inhaled Ciclesonide for Outpatient Treatment with Symptomatic COVID-19
The results of this randomized clinical trial demonstrated that ciclesonide did not achieve the primary efficacy end point of reduced time to alleviation of all COVID-19–related symptoms. A total of 413 participants... read more
1-year Mortality After COVID-19 ICU Admission
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes severe disease in some patients. Patients can experience severe disabilities after intensive care unit (ICU) admission due to coronavirus disease... read more
Post-acute Neurological Consequences of COVID-19
COVID-19 and its neurological consequences particularly burden marginalized communities, and so can only be effectively treated by advancing health equity. Our world has witnessed over 275 million confirmed cases of COVID-19... read more
Immunological Dysfunction Persists for 8 months Following Initial Mild-to-Moderate COVID-19 Infection
A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we studied individuals with LC compared to... read more
Effect of Early Fluvoxamine Treatment Among COVID-19 Patients
Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early diagnosed COVID-19 reduced the need for hospitalisation defined as retention in a COVID-19 emergency setting or transfer to... read more
Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients
Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo. A... read more
Omicron Magnifies the Distress in the Health Care Labor System
In December 2020, to the tune of rousing cheers, the first health care workers began getting vaccinated against COVID-19. A year later, the cheers have died down, vaccination rates have plateaued, and the Omicron wave... read more
COVID-19 Guidance for Hospital Reporting and FAQs
Hospitals are responsible for reporting the information to the Federal government. Facilities should report at the individual hospital level, even if hospitals share a Centers for Medicare & Medicaid Services (CMS) Certification... read more
Risk Factors for Severe COVID-19 Outcomes Among Adults Who Completed a Primary COVID-19 Vaccination
In this analysis of data from 465 U.S. health care facilities, severe COVID-19 outcomes (i.e., respiratory failure, ICU admission, or death) were rare among adults aged ≥18 years after primary vaccination. These findings... read more
